The short answer
There is no normal PSA for your age, in the sense of a number a guideline body has published as the boundary for someone your age. The NCI's PSA fact sheet, updated 31 January 2025, puts it directly: "There is no single threshold that distinguishes a normal versus an abnormal PSA result." It notes that in general a level above 4.0 ng/mL is treated as abnormal and may lead to a biopsy recommendation, and that some clinicians apply a higher cutoff such as 5 ng/mL for older men and a lower one such as 2.5 ng/mL for younger men. That is a description of what clinicians do, not a published standard.
Where the 4 ng/mL number came from
The 2026 amendment of the AUA/SUO Early Detection of Prostate Cancer guideline is unusually candid about this. Its own words: "The definition of an elevated PSA has changed over time. The commonly cited threshold of 4 ng/mL is based on very early studies that identify the highest levels typically observed among patients thought to be free of prostate cancer." In other words, 4 ng/mL was drawn from the upper edge of a distribution in men presumed healthy, not from an outcome trial.
The guideline adds that a second commonly cited threshold, 3 ng/mL, comes from the Finnish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC), which found a significant reduction in prostate cancer deaths among men who entered between ages 55 and 69 and were referred to biopsy on that threshold. So the two numbers most often quoted to patients have different origins and different strength of evidence behind them.
| Age band | Threshold value as cited | Status in the guideline |
|---|---|---|
| 40s | 2.5 ng/mL | Discussion text, no evidence grade |
| 50s | 3.5 ng/mL | Discussion text, no evidence grade |
| 60s | 4.5 ng/mL | Discussion text, no evidence grade |
| 70s | 6.5 ng/mL | Discussion text, no evidence grade |
What age actually decides
Age is genuinely load-bearing in this guideline. It just governs the schedule rather than the cutoff. These are the numbered statements, with the strength and evidence grade the panel assigned to each.
| Statement | What it says | Strength and grade |
|---|---|---|
| 4 | Clinicians may begin screening and offer a baseline PSA test to people between ages 45 to 50 | Conditional, Grade B |
| 5 | Clinicians should offer screening beginning at age 40 to 45 for people at increased risk based on Black race, germline mutations, or strong family history of prostate cancer | Strong, Grade B |
| 6 | Clinicians should offer regular screening every 2 to 4 years to people aged 50 to 69 | Strong, Grade A |
| 7 | Clinicians may personalize the re-screening interval, or discontinue screening, based on patient preference, age, PSA, prostate cancer risk, life expectancy and general health | Conditional, Grade B |
| 3 | For people with a newly elevated PSA, clinicians should repeat the PSA before a secondary biomarker, imaging, or biopsy | Expert Opinion |
| 9 | Clinicians should not use PSA velocity as the sole indication for a secondary biomarker, imaging, or biopsy | Strong, Grade B |
What a typical PSA looks like at each age
This is the honest version of the chart people are looking for, and it is a median rather than a cutoff. The AUA guideline reports median PSA levels of about 0.4 to 0.7 ng/mL in men in their 40s and about 0.7 to 1 ng/mL in men in their 50s. From the Malmö Preventive Project it reports medians of 0.68 ng/mL at ages 40 to 49, 0.88 ng/mL at 50 to 54 and 0.96 ng/mL at 55 to 59.
Those medians matter because of what sits on either side of them. In that same analysis, 82 percent, 71 percent and 86 percent of lethal prostate cancer cases occurred in men whose PSA was above the median for their age band. The guideline's reading is that this supports risk-stratified screening based on a midlife PSA, and that it should be considered in men aged 45 to 59. A single midlife number is more informative than the label normal or abnormal attached to it.
| Age | Median PSA | Source as cited in the guideline |
|---|---|---|
| 40s | About 0.4 to 0.7 ng/mL | Guideline discussion, reference 39 |
| 50s | About 0.7 to 1 ng/mL | Guideline discussion, reference 39 |
| 40 to 49 | 0.68 ng/mL | Malmö Preventive Project |
| 50 to 54 | 0.88 ng/mL | Malmö Preventive Project |
| 55 to 59 | 0.96 ng/mL | Malmö Preventive Project |
Sponsored option
Vetted Aug 19, 2026Affiliate link, we may earn a commission at no extra cost to you.
Sesame Our score 4.0/5
Telehealth / primary care
Pricing as of Aug 19, 2026
Telehealth visits from $34; weight-loss program $99/mo or $59/mo annual
If your PSA came back high
Repeat it first. The guideline reports that in people with a newly elevated PSA, the level returns to normal on retesting in 25 to 40 percent of cases. In the STHLM-3 study, among 1,686 biopsied patients with a PSA of 3 to 10 ng/mL who had two PSA tests 8 weeks apart, 283 of them, 17 percent, subsequently had a PSA below 3 ng/mL. That is the reasoning behind Statement 3: confirm a newly elevated result before proceeding to a biopsy, imaging or a second biomarker.
Several ordinary things raise PSA temporarily. The NCI lists infection or inflammation of the prostate and a recent prostate biopsy, either of which can keep the level up for a month or two, and notes that vigorous exercise such as cycling, and ejaculation, can raise it transiently. In the other direction, the 5-alpha reductase inhibitors finasteride and dutasteride lower PSA after at least six months of use. Older work suggested doubling the value for men taking them, though the AUA guideline cautions that the effect varies: one trial found only about a third of patients on 5-ARI therapy had a 40 to 60 percent decline at one year.
Our PSA reference page lists the ranges as their sources state them, each with its own effective date, and the prostate cancer screening page sets out the screening recommendation itself.
Where the USPSTF stands
The US Preventive Services Task Force recommendation on prostate cancer screening dates from 8 May 2018 and is currently being updated. For men aged 55 to 69 it is a Grade C: the decision to undergo periodic PSA-based screening should be an individual one. For men 70 and older it is a Grade D: the Task Force recommends against PSA-based screening. Note that this sits alongside, and does not match, the AUA's 50-to-69 screening window and its 45-to-50 baseline, which is worth knowing if two clinicians give you different advice.
Frequently asked questions
What is a normal PSA level for my age?
No guideline body publishes one. The National Cancer Institute states there is no single threshold that distinguishes a normal from an abnormal PSA result. The decade-by-decade values often shown in charts (2.5 ng/mL in the 40s through 6.5 ng/mL in the 70s) appear in the AUA/SUO 2026 guideline's background discussion, cited to work from 1993, and are not adopted by any numbered recommendation.
Is a PSA of 4 high?
4.0 ng/mL is the level above which a result is generally treated as abnormal and may prompt a biopsy recommendation, according to the NCI. The AUA guideline notes that this threshold came from very early studies of the highest levels seen in men presumed free of prostate cancer, rather than from an outcome trial. A single elevated reading is also not confirmation: it returns to normal on a repeat test in 25 to 40 percent of cases.
At what age should I start PSA testing?
The AUA/SUO guideline says clinicians may offer a baseline PSA between ages 45 and 50 (Conditional, Grade B), and should offer screening from age 40 to 45 for people at increased risk based on Black race, germline mutations or a strong family history (Strong, Grade B). The USPSTF frames it differently, as an individual decision between 55 and 69.
How often should PSA be checked?
Every 2 to 4 years for people aged 50 to 69, which is the AUA/SUO guideline's strongest age-based statement (Strong, Grade A). The interval can be personalized, or screening discontinued, based on preference, age, PSA, risk, life expectancy and general health.
Does PSA naturally rise with age?
Yes. The AUA guideline states that PSA generally increases with age in people without prostate cancer, and that this is what led to the idea of age-adjusted thresholds in the first place. Reported medians rise from about 0.68 ng/mL at ages 40 to 49 to about 0.96 ng/mL at 55 to 59. Rising with age is not the same as a published cutoff for your age.
What can raise PSA besides cancer?
The NCI lists prostate infection or inflammation and a recent prostate biopsy, which can elevate PSA for a month or two, plus vigorous exercise such as cycling, and ejaculation, which can raise it transiently. Finasteride and dutasteride lower it.
When to talk with a clinician
Before a first PSA test, so the decision to screen is one you made rather than one that happened to you, and again before any biopsy that follows a single elevated result. The guideline's own first statement is that clinicians should engage in shared decision-making and proceed based on your values and preferences. If your result is newly elevated, asking whether it should be repeated first is a reasonable question grounded in the guideline itself.
